Ближайшие и средне-отдаленные результаты эндопротезирования коронарных артерий стентами Xience V с лекарственным антипролиферативным покрытием Everolimus
Диссертация
Проведенный на большом материале научный анализ позволяет оптимизировать алгоритм и подход к лечению пациентов с ИБС, с сопутствующими факторами риска, влияющими на успех эндоваскулярных процедур. С целью снижения частоты возникновения рестеноза в среднеотдаленном периоде и необходимости повторного проведения эндоваскулярных процедур реваскуляризации миокарда, можно рекомендовать широкое… Читать ещё >
Содержание
- Список сокращений, использованных в диссертации
- Цель и задачи исследования
- ГЛАВА 1. Состояние вопроса по данным литературы
- 1. 1. Эпидемиология ИБС
- 1. 2. История развития эндоваскулярных методов лечения ИБС
- 1. 3. Современные эндоваскулярные методы лечения ИБС
- 1. 4. Рестеноз внутри стента. Механизмы рестенозирования после ЭВП. Факторы, влияющие на развитие т^егй стеноза
- 1. 5. Характеристика различных типов стентов (голометаллические и стентов с лекарственным покрытием) и их сравнение
- 1. 6. Исследования стентов с антипролиферативным лекарственным покрытием эверолимус- Х1епсе V
- 1. 7. Осложнения применения стентов с антипролефиративным лекарственным покрытием
Список литературы
- Бабунашвили A.M., Иванов В. А. Применение коронарного стентирования в зависимости от клинической картины ИБС и типа атеросклеротического поражения коронарного русла. // Москва, 2000, 77 сс.
- Бабунашвили A.M., Иванов В. А., Бирюков С. А. // Эндопротезирование венечных артерий сердца. // Москва, Издательство АСВ, 2001 г.
- Бабунашвили A.M., Рабкин И. Х., Иванов В.А.// Коронарная ангиопластика.// Москва, Издательство АСВ, 1996 г.
- Беленков Ю.Н., Самко А. Н., Батыралиев Т. А., Першуков И. В. Коронарная ангиопластика: взгляд через 30 лет. Кардиология, 2007- 9:4−13.
- Биленко М.В. Ишемические и реперфузионные повреждения органов:-М., Медицина, 1989.
- Бокерия Л.А., Алекян Б. Г., Коломбо А., Бузиашвили Ю. И. Интервенционные методы лечения ишемической болезни сердца. // Редакция НЦССХ РАМН, 2002, 417с.
- Бокерия Л.А., Алекян Б. Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации -2011г.
- Вальгма К., Вельбри С., Кулл М. и др. результат изучения патогенеза и клинические аспекты ишемической болезни сердца в Тартуском государственном университете. Klin Med (Mosk). 1972 -50(12): 125−30.
- Велихов Е. П., Иоселиани Д. Г., Гнеденко В. Г., Файнберг Е. М. Информационно-коммуникационные технологии в интервенционной кардиологии радиологии. Международный Журнал интервенционной кардиоангиологии, № 8 2005, стр. 48 56, г. Москва.
- Велихов Е. П., Иоселиани Д. Г., Гнеденко В. Г., Файнберг Е. М. Компьютеризированный комплекс «ДИМОЛ-ИК» для автоматизации лечебно-диагностического процесса в кардиологии и кардиохирургии.
- Специализированный медицинский журнал «Главный врач юга России», № 3 2005, стр. 26 35, г. Ростов на Дону.
- Волова Т. Г., Севастьянов В. И., Шишацкая Е. И. Полиоксиалканоаты -биоразрушаемеы полимеры для медицины. 2-е изд. Красноярск: 2006. -287 с.
- Грег В. Стоун- «НОВОСТИ ABBOTT VASCULAR В РОССИИ», 2008 № 3 (6) 2, Вашингтон, США, ТСТ-2008.
- Иоселиани Д.Г., Араблинский A.B., Чернышева И. Е. Непосредственные результаты стентирования коронарных артерий прямым способом . Кардиология. 2002−42(2):8−10.
- Иоселиани Д.Г., Колединский А. Г., Кучкина Н.В. Ограничивает ли внутрикоронарное введение фосфокреатина реперфузионное повреждение миокарда при ангиопластике инфарктответственной коронарной артерии в остром периоде инфаркта миокарда? ч
- Международный журнал интервенионной кардиоангиологии. 2004,6: 11−16.
- Кобешавидзе Н.В., Семитко С. П., Громов Д. Г. и др. Результаты использования коронарных стентов Вх Sonic Вх Velocity (Cordis, а Johnson) у больных с различными формами ИБС. Международый журнал интервенионной кардиоангиологии, 2006, 10: 11−15.
- Крюков H.H., Николаевский E.H., Поляков В.П.- ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА Современные аспекты клиники, диагностики, лечения, профилактики, медицинской реабилитации, экспертизы 2010, стр. 88.
- Мухарлямов, Н. М. Ю.Н. Беленков. Ультразвуковая диагностика в кардиологии. М. ¡-Медицина, 1981. 156 с.
- Петросян Ю.С., Зингерман JI.C. Коронарография. // М. Медицина, 1974 г. стр. 150.
- Самко А.Н., Буза В. В., Карпов Ю. А. Место коронарного стентирования в лечении ишемической болезни сердца. // Русский Медицинский Журнал Том 10, № 19, 2002, Стр. 851−854.
- Ступаков И.Н., Гудкова Р. Г. Организация работы медицинских отделений и служб, медицинские экспертизы пациентов. Журнал «Здравоохранение 7"-2008.
- Файнберг Е. М., Иоселиани Д. Г. Электронная история болезни для кардиологических клиник. Международный Журнал интервенционной кардиоангиологии, № 16 2008, стр. 40 48, г. Москва.
- АСС/АНА Percutaneous Coronary Intervention in United States. // J Am ColCardiol 2002- 23- 2: 1881−2137.
- Ako J., Morino Y., Honda Y., et al. Late incomplete stent apposition following sirolimus eluting stent: serial quantitative intravascular ultrasound analysis from the SIRIUS trial. // J Am Coll Cardiol 2003- 41(Suppl A): 33A.
- Alt E., Haehnel I., Beilharz C. et al. Inhibition of neointima formation after experimental coronary stenting. // Circulation 2000- 101: 1453−8.
- Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol. 1985−6(6): 1233−8.
- Antoniucci D., Santoro G., Bolognese L., et al. // A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction (FRESCO) // J Am Coll Cardiol 1998- 31:1234−1239.
- Aoki J., Kirtane A., Martin B. Leon Coronary Artery Aneurysms After Drug-Eluting Stent Implantation. J Am Coll Cardiol Intv, 2008- (1) 14−21.
- Applegate RJ, Hermiller JJ, Sanz M, et al. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2- year results from the SPIRIT III randomised trial. Eurolntervention 2010- 6:437−46.
- Beyar R., Roguin A. The sirolimus-coated stent: will the Achilles heel of interventional cardiology finally be cured? // Eur Heart J 2001- 22: 2054−7.
- Bezzera H.G. et al. Assessment of coronary stent by optical coherence tomography, methodology and definitions. The Int J of Cardiovascular Imaging. February 201- 27: Issue 2, 259−269.
- Block P., Petch M.C., Letouzey J.P. Manpower in cardiology in Europe // Eur Heart J 2000- 21- 14: 1135−40.
- Bruke S.E., Labbers N.L., Chen Y.W. et al. Neointimal formation after ballon-induced vascular injury in Yucatan minipigs is reduced by oralrapamycin. //j Cardiovasc Pharm 1999- 33: 829−835.
- Burzotta F, Sivigliaa M, Altamura L. et al. Outcome of Overlapping Heterogenous Drug-Eluting Stents and of Overlapping Drug-Eluting and Bare Metal Stents. American Journal of Cardiology 2007. 99, (3), 364−368.
- Camenzind E., Steg P.G., Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a causefor concern. Circulation. 2007: 20- 115(11):1440−55.
- Catala L. // Is stent design affecting the biologic response. // In: „Endovascular Therapy Daily“, at the „eight complex coronary angioplasty“, 1. Paris, 1997: p.2.
- Centemero MP, Stadler JR. Stent thrombosis: an overview. Expert Rev Cardiovasc Ther. 2012- 10(5):599−615.
- Chi Hang Lee, Patrick W Serruys, An overview of drug-eluting stent. International Journal of interventional Cardioangiology. 2003: 1,9−16.
- Colombo A., Tobis J. Techniques in Coronary Artery Stenting. // Martin Dunitz Ltd. 2000- 422.
- Dangas G., Mehran R., Lansky A.J., et al. Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. // Am J Cardiol 2000- 86: 777.
- Donaldson K.L., Goolsby G.L., Kiener P.a., et al. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994- 5:1041−50.
- Edelman E.R., Rogers C. // Hoop Dreams. Stent without restenosis. // Circulation, 1996, 94(6): 1199−202.
- Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007: 10−297(2): 159−68. Epub 2006.
- Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polimer-coated stent. Circulation 2001−104:473−9.
- Farooq V, Brugaletta S, Serruys PW. The SYNTAX score and SYNTAX-based clinical risk scores. Semin Thorac Cardiovasc Surg. 2011 Summer- 23(2):99−105.
- Fejfar Z. Prevention and control of the epidemics of ischaemic heart disease. An international problem. Arch Klin Med. 1969−216(3): 184−200.
- Fishman D.L., Leon M.B., Baim D.S., et al. // A randomized comprision of coronary-stent placement and balloon angioplasty in treatment of coronary artery disease. Stent Restenosis Study Investigators. // N Engl G Med 1995: 23−332 (8) 536.
- Garas S.M., Huber P., Scott N.A. // Overview of therapies for prevention ofrestenosis after coronary interventions. // Pharmacol Ther 2001- 92(2−3): 165- 78.
- Garg S, Serruys P, Onuma Y, et al. 3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions The SPIRIT II Trial. JACC 2009- 2 (12): 1190−8.
- George D. Dangas, MD, Bimrner F. et al. In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of American College of Cardiology 2010 -Vol. 56 № 23, 2010.
- Gianturco C., Wright K.C., Wallace S., et al. // Percutaneous endo-vascular stents: An experimental evaluation. //Radiology. 1985 jul, 156 (l):69−72.
- Giesen Van W.J., Lincoff M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymersin porcine coronary arteries. // Circulation 1996- 94: 1690−1697.t
- Grenadier E., Roguin A., Hertz I., et al. Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphoryl-choline-coated coronary stent. // Catheter Cardiovasc Interv 2002- 55: 303−8.
- Grossman W., Baim D. Coronary angiography In: Cardiac Catheterization, Angiography and Intervention. Editors Grossman W, Baim D. Lea&Febiger, 1991: 185−214.
- Gruentzig A. Transluminal dilatation of coronary-artery stenosis. // Lancet 1978- 1:263.
- Guterman LR, Hopkins LN. Endovascular treatment of cerebral aneurysms. Diagnosis and treatment. Clin Neurosurg. 1993−40:56−83. Review.
- Hegger MJ. A fresh approach to group goal setting. The three-way rotation nomimal group technique. J Nurs Staff Dev. 1986, 2(1): 13−7.
- Heldman A.W., Cheng L., Jenkins G.M. et al. Paclitaxel stent coating inhibitis neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001- 103: 2289−95.
- Heldman G.P. Internal testing of DES. // Circulation 2001- 103: 2289−95.
- Hloucal L, Dusek. Epidemiologic studies of coronary sclerosis and myocardial infarct. Wien Med Wochenschr. 1969:11- 119(2):27−31.
- Hoffmann R., Mintz G.S., Mehran R/, et al. Tissue proliferation within and surrounding Palma-Schatz stents in dipendent on the aggressivenessof stent implantation technique. Am Cardiol 1999−83:1170−4.
- Hofma HS., Whelan DM. van Beusekom HM. et al. // Increasing arterial wall injury after long-term implantation of two types of stents in a porcine coronary model. // Eur Heart j., 1998, 19: 601.
- Hofma S.H., Beusekom H.M., Serruys P.W., et al. Recent developments in coated stents. // Curr Intervent Cardiol Rep 2001- 3: 28−36.
- Hwang C.W., Wu D., Edelman E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001−104:600−5.
- Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. // JAMA 2005- 293: 2126 -2130.
- James H.F. Rudd, John R. et al. Atherosclerotic Biology and Epidemiology of Disease, edt: Topol Eric J. Textbook of cardiovascular medicine.
- Joner M, Finn AV, Farb A, et. al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006−48:193−202.
- Kappetein AP. Optimal revascularization strategy in patients with three-vessel disease and/or left main disease: The 2-year outcomes of the SYNTAX trial. Presented at: ESC Congress 2009- September 2, 2009- Barcelona, Spain.
- Karvouni E. 17 months after SES implantation despite ASA continuation (clopidogrel stoped at 12 months). // Heart 2005- 8: 64−71.
- Kedhi E., Joesoef K.S., McFadden E., et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010- 375:201−9.
- King S. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience. // J Am Coll Cardiol 1993- 22- 2:353−360.
- Klauss V. Leaders: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymervs. Sirolimus-Eluting Stents with a Durable Polymer, in TCT (2009).
- Lablanche J. M, Cathet. and Cardiovasc.Diagn. 17:97−98 (1989).
- Lafont A., Guzman L.A., Whitlow P.L., et al. Resteosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995- 76:996- 1002. (обсуждение).
- Lee SH, Jang Y, Oh SJ, Park KJ. Overlapping vs. one long stenting in long coronary lesions. Catheter Cardiovasc Interv. 2004−62(3):298−302.
- Lukenda J, Biocina-Lukenda D. Stent, endovascular prosthesis, net or strut? What would British dentist Charles Stent (1807−1885) have to say on all this?. Lijec Vjesn. 2009−131(l-2):30−3.
- Macander PJ, Agrawal SK, Roubin GS. The Gianturco-Roubin balloon-expandable intracoronary flexible coil stent. J Invasive Cardiol. 1991- 3(2):85−94. Review.
- Malik N., Gunn J., Shepherd L., et al. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. //
- J. Invasive Cardiol 2001- 13: 193−201.
- Margulies HS. Report of Inter-Society Commission for Heart Disease Resources. Foreword. J Am Osteopath Assoc. 1970−69(11):1118−9.
- McGovern P.G., Pankow J.S., Shahar E., et al. Recent trends in acute coronary heart disease mortality, morbidity, medical care, and risk factors: the Minnesota Heart Survey Investigators. // N Engl J Med 1996−334: 884 890.
- Mehran R., Dangas G., AbizaidA. et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999- 100:1872−1878.
- Moses J.W., O’Schaughnessy C., Caputo R., et al. The U.S. multicenter, randomized, double-blind study of the sirolimus-eluting stent in coronary lesions: safety outcomes at 9 months. Eur Heart J 2002−23:264.
- Nikolsky E, Lansky AJ, Sudhir K, et al. SPIRIT IV trial design: a large-eluting stents in patients with coronary artery disease. Am Heart J 2009- 158:520−6.
- Onuma Y, Tanimoto S, Ruygrok P, et al. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study.
- Catheter Cardiovasc Interv 2010−76 (5):634−42.
- Piek JJ, Neumann FJ, Giessen WJ, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention 2005−1:266−72.
- Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibitis vascular smooth muscle cell migration. J Clin invest 1996- 98: 2277−83.
- Raber L, Juni P, Nuesch E, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol. 2011- 57(21):2143−51.
- Reddy K.S., Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. // Circulation 1998- 97: 596 601.
- Rodrigues A, Ayala F, Bernardi V, et al. Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS). J Am Coll Cardiol. 1998- 32: 1351−7.
- Roger VL. Epidemiology of myocardial infarction / V.L. Roger // Med Clin North Am.- 2007 .- Jul, 91(4).- P. 537 552.
- Rogers C., Edelman ER. // Endovascular stent design dictates experimental restenosis and thrombosis. // Circulation, 1995, 91: 2995−3001.
- Ryan T. J: Refining the classification of chest pain: A logical next step in the evaluation of patients for acute cardiac ischemia in the emergency department//Ann Emerg Med 29: 166−168, 1997.
- Sawada Y., Nokasa H., Kimura T., et al. // Initial and six months outcome of Palmaz-Schatz stent implantation: STRESS/BENESTENT equivalent vs non-equivalent lesions.// J. Am Col Cardiol 1996- 27 (suppl A): 252A.
- Seldinger S.I. Catheter replacement of the needle in percutaneous arteriography: a new technique. // Acta Radiol 1953- 39: 368.
- Serruys P.W. ARTS I the rapamycin eluting stent- ARTS It — the rosy prophecy. // Eur Heart J 2002- 23: 757.
- Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease: BENESTENT study group. // N Engl J Med 1994- 331: 489−509.
- Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Eurolntervention. 2005-l (l):58−65.
- Sharma SK, Karakala V, Dangas G, D. et al. // In-stent restenosis after Palmaz-Schatz stent implantation. // Eur Heart J 1998- 20: 352.
- Sigwart U., Puel J., Mirkovitch V., et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med., 1987- 326: 701−6.
- Sigwart U., Urban P., Golf S., et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. // Circulation 1988- 78: 1121−1127.
- Silva-Orrego P, Bigi R, Colombo P, et al. Direct stenting after thrombus removal before primary angioplasty in acute myocardial infarction. J Interv Cardiol. 2008 Aug-21(4):300−6.
- Sousa J.E., Costa M.A., Abizaid A.C., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. // Circulation 2001- 104: 2007.
- Stabile E., Escolar E., Weigold G., et al. Marked malposition and aneurysm formation after sirolimus-eluting coronary stent implantation. // Circulation 2004- 110(5): 47−8.
- Stamler J. Prevention in coronary heart disease. Singapore Med J. 1974−15(l):4−24.
- Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare- metal stents: a collaborative network metaanalysis. Lancet 2007- 370:937−48.
- Stone G.W., Rizvi A., Newman W., et al. A large-scale randomaized comparison of Everolimus-eluting and paclitaxel-eluting stents: one year clinical outcomes from the SPIRIT IV trial. Am J Cardiol 2009- 104: XV.
- Stone G. W, Midei M., Newman W. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. SPIRIT III Investigators. JAMA. 2008: 23 -299(16): 1903−13.
- Stone G.W., Rizvi A., Newman W., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010- 362:1663−74.
- Suzuki T, Kopia G. Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. // Circulation 2001- 104:1188−1193.
- Topaz O, Vetrovek G. // The stenotic stent: mechanism and revascularization options. // Cathet Cardiovasc Diagn 1996- 37:293−9.
- Tsuchida K, Garca-Garca HM, Ong AT, et al. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv 2006- 67:188−97.
- Udipi K., Melder R.J., Chen M. et al."The next generation Endeavor Resolute Stent: role of the BioLinx polymer system» Medtronic caediovascular, Santa Rosa, CA 95−403, USA.
- Udupi K. Next generation Endeavor Resolute Stent: role of the BioLinx polymer system. Medtronic cardiovascular, Santa Rosa, CA 95−403, USA.
- Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. //N Engl J Med 1988- 319: 332−337.
- Versaci F., Gaspardone A., Tomai F., et al. A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. The New England journal of medicine 1997- 12:817.
- Vik-Mo H., Wiseth R., Hegbom K. Coronary aneurysm after implantation of a paclitaxel-eluting stent. // Scand Cardiovasc J 2004- 38(6): 349−52.
- Wahl A.F., Donaldson K. L, Fairchild C, et al. Loss of normal P53 function confers sensitization to Taxol by increasing G2/m arrest and apoptosis. Nat med 1996- 2:72−9.
- Wakabayashi K., Lindsay J., Laynez-Carnicero A., et al. Utility for Intravascular ultrasound guidans in patients undergoing percutaneus coronary intervention for type C lesions. J Interv Cardiol 2012- 25:452−9.
- Waksman R., Bhargava B., Taafe M., et al. Prolonged antiplatelet therapy to reduce late thrombosis after intracoronary gamma radiation in patients with in-stent restenosis: «plavix-wrist» // Circulation 2000- 102: II- 570.
- Waters R.E. 3 cases following DES for in-stent-restenosis (at 16, 20, 43 months) shortly after interruption of antiplatelet Tx. // Catheter Cardiovasc Interv // 2005- 4: 107−115.
- Wenaweser P., Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005−46(5):CS5−6.
- Whelan D.M., Van Giessen W.J., Krabbendam S.C., et al. Biocompatibilrty of phosphorylcholine coated stents in normal porcine coronary arteries. // Heart 2000- 83: 338−45.
- Whelan D.M., van Beusekom H.M., van Giessen W.J. Mechanisms of drug loading and release kinetics. Semin Interv Cardiol 1998−3:127−31.
- Windecker S. Biolimus-eluting stent with biodegradable polymer versus Sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non inferiority trial. Lancet 2008- 372- 9644:1163−1173.
- Zakharova OV, Arablinskii AV, Ioseliani D.G. Endovascular treatments in coronary heart disease patients with restenosis after primary ballon angioplasty. Klin Med (Mosk). 2004- 82(10):22−6.
- Zilberman M., Eberhart R.C. Drug-eluting bioresorbable stents for various applications. Annu Rev Biomed Eng. 2006- 8:153−80.